A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Boumendjel, Ahcene ^a   McLeer Forin, Anne ^a,d   Champelovier, Pierre ^a,d   Allegro, Diane ^c   Muhammad, Dima ^a   Souard, Florence ^a   Derouazi, Madiha ^b   Peyrot, Vincent ^c   Toussaint, Bertrand ^b   Boutonnat, Jean ^a,d  

^a CNRS   (France)

^b LABORATOIRE TIMC IMAG   (France)

^c University of the Mediterranean Aix Marseille II   (France)

^d HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHALCONE DERIVATIVE; COLCHICINE; GLYCOPROTEIN P; JAI 51; TUBULIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN; CHALCONE; DRUG DERIVATIVE; JAI-51;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; C57BL 6 MOUSE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; FLOW CYTOMETRY; GLIOBLASTOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MICROTUBULE ASSEMBLY; MITOSIS INDEX; MOUSE; NONHUMAN; ULTRACENTRIFUGATION; ANIMAL; BRAIN TUMOR; C57BL MOUSE; DRUG ANTAGONISM; METABOLISM; MICROTUBULE; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHALCONE; CHALCONES; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED C57BL; MICROTUBULES; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCR; RATS;

EID: 68349130136     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-242     Document Type: Article

References (32)

1. Collins VP Brain tumours: Classification and genes J Neurol Neurosurg Psychiatry 2004 75(Suppl 2):iI2-11. 1765661 15146033 10.1136/ jnnp.2004.040337
2. Stupp R Hegi ME Bent van den MJ Mason WP Weller M Mirimanoff RO Cairncross JG Changing paradigms - an update on the multidisciplinary management of malignant glioma Oncologist 2006, 11(2):165-180. 10.1634/ theoncologist.11-2-165 16476837
3. Aschner M Fitsanakis VA dos Santos AP Olivi L Bressler JP Blood-brain barrier and cell-cell interactions: Methods for establishing in vitro models of the blood-brain barrier and transport measurements Methods Mol Biol 2006, 341:1-15. 16799185
4. Eisenblatter T Huwel S Galla HJ Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier Brain Res 2003, 971(2):221-231. 10.1016/S0006-8993(03)02401-6 12706238
5. Loscher W Potschka H Blood-brain barrier active efflux transporters: ATP-binding cassette gene family NeuroRx 2005, 2(1):86-98. 539326 15717060 10.1602/neurorx.2.1.86
6. Begley DJ ABC transporters and the blood-brain barrier Curr Pharm Des 2004, 10(12):1295-1312. 10.2174/1381612043384844 15134482
7. Breedveld P Pluim D Cipriani G Wielinga P van Tellingen O Schinkel AH Schellens JH The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients Cancer Res 2005, 65(7):2577-2582. 10.1158/0008-5472.CAN-04-2416 15805252
8. Breedveld P Beijnen JH Schellens JH Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs Trends Pharmacol Sci 2006, 27(1):17-24. 10.1016/ j.tips.2005.11.009 16337012
9. Youdim KA Qaiser MZ Begley DJ Rice-Evans CA Abbott NJ Flavonoid permeability across an in situ model of the blood-brain barrier Free Radic Biol Med 2004, 36(5):592-604. 10.1016/j.freeradbiomed.2003.11.023 14980703
10. Hadjeri M Barbier M Ronot X Mariotte AM Boumendjel A Boutonnat J Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues J Med Chem 2003, 46(11):2125-2131. 10.1021/ jm021099i 12747785
11. Boumendjel A Nicolle E Moraux T Gerby B Blanc M Ronot X Boutonnat J Piperazinobenzopyranones and phenalkylaminobenzopyranones: Potent inhibitors of breast cancer resistance protein (ABCG2) J Med Chem 2005, 48(23):7275-7281. 10.1021/jm050705h 16279786
12. Boumendjel A Boccard J Carrupt PA Nicolle E Blanc M Geze A Choisnard L Wouessidjewe D Matera EL Dumontet C Antimitotic and antiproliferative activities of chalcones: Forward structure-activity relationship J Med Chem 2008, 51(7):2307-2310. 10.1021/jm0708331 18293907
13. Andreu JM Gorbunoff MJ Lee JC Timasheff SN Interaction of tubulin with bifunctional colchicine analogues: An equilibrium study Biochemistry 1984, 23(8):1742-1752. 10.1021/bi00303a025 6722122
14. Barbier P Gregoire C Devred F Sarrazin M Peyrot V In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: Molecular modeling of the mechanism of action of a new antimitotic drug Biochemistry 2001, 40(45):13510-13519. 10.1021/bi010926z 11695898
15. Weisenberg RC Borisy GG Taylor EW The colchicine-binding protein of mammalian brain and its relation to microtubules Biochemistry 1968, 7(12):4466-4479. 10.1021/bi00852a043 5700666
16. Lee JC Frigon RP Timasheff SN The chemical characterization of calf brain microtubule protein subunits J Biol Chem 1973, 248(20):7253-7262. 4743522
17. Andreu JM Timasheff SN Conformational states of tubulin liganded to colchicine, tropolone methyl ether, and podophyllotoxin Biochemistry 1982, 21(25):6465-6476. 10.1021/bi00268a023 7150568
18. Schuck P Rossmanith P Determination of the sedimentation coefficient distribution by least-squares boundary modeling Biopolymers 2000, 54(5):328-341. 10.1002/ 1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P 10935973
19. Romagnoli R Baraldi PG Carrion MD Cara CL Cruz-Lopez O Preti D Tolomeo M Grimaudo S Di Cristina A Zonta N et al Design, synthesis, and biological evaluation of thiophene analogues of chalcones Bioorg Med Chem 2008, 16(10):5367-5376. 10.1016/j.bmc.2008.04.026 18440234
20. Liu XL Tee HW Go ML Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein Bioorg Med Chem 2008, 16(1):171-180. 10.1016/j.bmc.2007.10.006 17964170
21. Chang JY Chang CY Kuo CC Chen LT Wein YS Kuo YH Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells Mol Pharmacol 2004, 65(1):77-84. 10.1124/ mol.65.1.77 14722239
22. Tait SW Green DR Caspase-independent cell death: Leaving the set without the final cut Oncogene 2008, 27(50):6452-6461. 10.1038/onc.2008.311 18955972
23. Kitagawa K Niikura Y Caspase-independent mitotic death (CIMD) Cell Cycle 2008, 7(8):1001-1005. 18414023
24. Saif MW Tytler E Lansigan F Brown DM Husband AJ Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers Expert Opin Investig Drugs 2009, 18(4):469-479. 10.1517/ 13543780902762835 19278301
25. Kasibhatla S Baichwal V Cai SX Roth B Skvortsova I Skvortsov S Lukas P English NM Sirisoma N Drewe J et al MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps Cancer Res 2007, 67(12):5865-5871. 10.1158/ 0008-5472.CAN-07-0127 17575155
26. Peyrot V Leynadier D Sarrazin M Briand C Menendez M Laynez J Andreu JM Mechanism of binding of the new antimitotic drug MDL 27048 to the colchicine site of tubulin: Equilibrium studies Biochemistry 1992, 31(45):11125-11132. 10.1021/bi00160a024 1445852
27. Kim do Y Kim KH Kim ND Lee KY Han CK Yoon JH Moon SK Lee SS Seong BL Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin J Med Chem 2006, 49(19):5664-5670. 10.1021/jm050761i 16970393
28. Lee JS Paull K Alvarez M Hose C Monks A Grever M Fojo AT Bates SE Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen Mol Pharmacol 1994, 46(4):627-638. 7969041
29. Seelig A Landwojtowicz E Structure-activity relationship of P-glycoprotein substrates and modifiers Eur J Pharm Sci 2000, 12(1):31-40. 10.1016/S0928-0987(00)00177-9 11121731
30. Sawyer AJ Piepmeier JM Saltzman WM New methods for direct delivery of chemotherapy for treating brain tumors Yale J Biol Med 2006, 79(3-4):141-152. 1994797 17940624
31. Borlongan CV Emerich DF Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: Laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport Brain Res Bull 2003, 60(3):297-306. 10.1016/S0361-9230(03)00043-1 12754091
32. Omuro AM Faivre S Raymond E Lessons learned in the development of targeted therapy for malignant gliomas Mol Cancer Ther 2007, 6(7):1909-1919. 10.1158/1535-7163.MCT-07-0047 17620423